Archives
Latebreakers

Digital Family Planning: the Future is Now

Irregular Bleeding Due to Contraceptives

When she’s low on libido…

Ouch! Best approaches to menstrual pain

Contraceptive efficacy: understanding how user and method characteristics play their part

Strategizing treatment for chronic heavy menstrual bleeding

Perimenopause

Untangling the literature on obesity and contraception

High tech apps for no-tech FABM

Menstrual exacerbation of other medical conditions

From Princeton University: Thomas James Trussell (1949-2018)

The Short and Long of IUD Use Duration

Selecting a Method When Guidance Isn’t Clear-cut

Healthcare in the Time of Digital Expansion

The Scoop on Two New FDA-Approved Contraceptive Methods

Pregnancy of unknown location—meeting the challenge

Big “yes” (with caveats) to CHCs during perimenopause

The role of IUDs (LNG IUDs, too!) in emergency contraception

Combined pills’ effect on mood disorders

Abortion in the U.S.: safe, declining, and under threat

Hope for ovarian cancer screening test

Breast cancer still a small risk with some hormonal contraceptives

New treatment modality for BV

Record rate of HPV-related throat cancer

Viruses in semen potentially transmissible

Don’t Abstain from Your Role in Abstinence

Teens births declining but geographic ‘hotspots’ defy trend

Online Medical Abortion Service Effective and Safe

Do Women Really Need to Wait That Long?

Reassuring news on depression and OC use

PMDD: Genetic clues may lead to improved treatment

Breast cancer risk when there is a family history

Body weight link to breast and endometrial cancers (and 11 others)

Family Planning in 2017 and Beyond

Make Me Cry: Depression Link (Again)?

Managing implant users’ bleeding and spotting

Zika: Updated guidance for providers

Pharmacist-prescribed contraceptives

Hot off the press! 2016 MEC and SPR

Zika virus fears prompt increased request for abortion in nations outlawing abortions

Opioid use epidemic among reproductive-age women

Good news on the family planning home front!

War Against Planned Parenthood Hurts Women

Win-win for both treatment and prevention

Center of the Storm

Ambivalence

Menopause, mood, mental acuity, and hormone therapy

Emergency contraception for teens

Postpartum Contraception: Now, Not Later

Reproductive tract infections, sexually transmitted infections, or sexually transmitted diseases: “a rose by any other name…”

Are we practicing what we preach?

Be alert to VTE in hormonal contraceptive users

LARC among teens increased 15-fold, but not enough

Brain cancer and hormonal contraception

Free tools: Easy access to the US Medical Eligibility Criteria for Contraceptive Use

Alcohol consumption when pregnancy is unwanted or unintended

Latest Data on Contraceptive Use in the United States

LateBreaker sampler from Contraceptive Technology conference

Emergency Contraceptive Pill Efficacy and BMI/Body Weight

Handout on Unintended Pregnancy and Contraceptive Choice

Ask About Withdrawal (Really!)

Rules to Practice By: Safety First and Cleanliness is Close to. . .

What’s Vanity Fair Got Against the NuvaRing?

Promising New Treatment for Hepatitis C

Numbers matter, so make them simple for patients

The Recession’s Effect on Unintended Pregnancies

Lessons Learned from the Contraceptive CHOICE Project: The Hull LARC Initiative

Applying the “New” Cervical Cytology Guidelines in Your Practice

Acute Excessive Uterine Bleeding: New Management Strategies

Medical indications for IUD use in teens

Whatever happened to PID?

Update on Emergency Contraception

Contraceptivetechnology.com New and Improved

Strategizing treatment for chronic heavy menstrual bleeding
June 2019

 

Can you stop her flooding? About 30% of women report heavy menstrual bleeding (HMB). For many of them, that flooding is chronic. There are several treatment options for chronic HMB, but how do they compare over the long run? Any treatment needs to account for the age of the patient, the severity of symptoms, the presence of other pelvic pathology, and near-term plans for childbearing. Which are the clear front-runners in the treatment strategy? And what about new therapies coming down the pipeline? Anita Nelson and Lee Shulman describe a framework for choosing the most effective treatments.[1]

Although the differential diagnoses of causes of HMB is extensive, the definition of what constitutes HMB need not be. A key factor in making a diagnosis of HMB is not only the amount of blood being lost, which is difficult to quantify, but how much HMB disrupts one’s life. Only about half of patients will be found to have any identifiable anatomical pathology. Patients with HMB more often have functional problems such as coagulopathy, excessive fibrinolysis, prostaglandin imbalances, vessel instability, or systemic causes.

Table 1. PALM-COEIN classification system for abnormal nongestational uterine bleeding

 

Treatment options

Treatment for chronic HMB can be directed to correct the pathophysiology underlying HMB or it can simply attempt to suppress the endometrium, especially if there are only local causes for the HMB, explain Drs. Nelson and Shulman.

Hormonal Therapies

Hormonal therapies are also available and are more effective than nonhormonal medications in treating HMB.[2] Progestins form the basis of hormonal therapies to effectively control chronic excessive menstrual blood loss.

  • The LNG intrauterine contraceptive is the most effective medical therapy for HMB and in many cases it is more effective than procedures such as ablation and hysterectomy (for more detail, see below).[3] The LNG-IUS 20 (Mirena) is approved for the treatment of HMB by the U.S. FDA and by regulatory authorities in over 100 other countries. In clinical trials of women with HMB documented by eluting hemoglobin from sanitary pads, women who randomized to this LNG intrauterine contraceptive had a median reduction in blood loss of 62% by 3 months and a 71% reduction by 6 months.[4] The LNG-IUS is also effective for controlling bleeding from most of the PALM-COEIN causes of HMB[5] (see Table 1) and is effective in women using oral anticoagulant therapy.[6] It is also the most effective medical therapy for endometrial hyperplasia and it reduces HMB and pain due to adenomyosis.[7]
  • Cyclic progestin (medroxyprogesterone acetate (MPA) 10 mg or norethindrone acetate (NETA) 5 mg) daily for 10 days a month is most useful for patients with chronic anovulation. Unexpectedly, these luteal phase therapies can increase blood loss in women who ovulate and have monthly cycling.
  • Progestin-only pills, progestin injections, and progestin-containing intrauterine contraceptives offer variable control of bleeding as well as contraceptive protection. The progestin-only pill (POP) decreases estrogen-stimulated endometrial proliferation.
  • DMPA initially increases unscheduled spotting and bleeding, but over the longer term, it usually results in cessation of spotting and bleeding.[8] DMPA is a first-line treatment for patients with underlying bleeding disorders.
  • Oral combined contraceptive. There is one product (Natazia) that is approved by the FDA for treatment of heavy or prolonged menstrual bleeding. In clinical trials of this estradiol valerate (E2V)/dienogest multiphasic pill, the reduction in blood loss reduction was almost as great as that seen in the U.S. clinical trials of Mirena for treatment of HMB.[9] However, other COC formulations are routinely used off-label to reduce cyclic bleeding. Most of the studies demonstrating clinical efficacy of COCs in the treatment of HMB are based on higher dose formulations, but there is one clinical trial of a 20 mcg EE pill that reduced menstrual blood loss by 68%.[10]
  • Contraceptive vaginal ring (NuvaRing). Cyclic use has been found to be more effective than COCs in treating HMB because it offered better cycle control.[11]
  • Extended-cycle COCs or vaginal rings also reduces total blood loss in patients with HMB by reducing the numbers of episodes of scheduled bleeding as well as the amount of blood lost per episode.[12],[13]
  • Other agents that are effective for short-term use include GnRH agonists, such as leuprolide acetate (Lupron), nafarelin acetate (Synarel) and goserelin acetate (Zoladex), or buserelin (Suprecur). Pseudomenopause is induced after about two weeks of use and amenorrhea rates approach 90%.[14] Because of concerns about osteoporosis and other hypoestrogenic conditions, the duration of GnRH agonists use is generally limited to 4 to 6 months unless an estrogen-progestin add-back is given.

Nonhormonal therapies

  • NSAIDS.     When taken from the onset of menses until the end of the heavy flow days, NSAIDs can reduce total menstrual blood loss by 20% to 45% and offer the additional benefit of analgesia for pain associated with uterine cramping. A Cochrane Systematic Database Review demonstrated that blood loss reduction was not affected by the particular NSAID used, but found that low-dose NSAIDs were far less effective than high-dose regimens.[15] NSAIDs can also be used in conjunction with other therapies (such as hormonal therapies) to boost the efficacy of those treatments. Patients with peptic ulcers and those who have coagulation disorders should avoid NSAIDs or couple the therapy with proton-pump inhibitors (PPIs).
  • Antifibrinolytic agents. The antifibrinolytic agent, tranexamic acid, has been used in Europe for treatment of HMB for more than 3 decades and is available over-the-counter in some of those countries. In clinical trials, women who used this tranexamic acid regimen (650 mg 2 tabs orally 3 times a day for up to the first 5 days of menses) experienced a 40% reduction in menstrual blood loss.[16] Reflecting previous theoretical concerns that drugs that block lysis of fibrin clots might create a hypercoagulable state, the FDA labeling for Lysteda advises caution in prescribing this product for women who use hormonal contraceptives (presumably only those with estrogen). These agents can also be helpful in women with von Willebrand disease especially in conjunction with hormonal treatments.[17]

Procedures

  • Outpatient endometrial ablation has been popular for the treatment of HMB. At their peak, ablations were almost as common as hysterectomies in the United States. Compared with endometrial ablation, the high-dose LNG IUS has a better record of cost, safety, and reversibility, making it a first-line therapy, and there is no difference in efficacy of endometrial ablation and LNG intrauterine therapy.[18]
  • Hysterectomy is the ultimate therapy, but studies have also demonstrated a comparable benefit of the high-dose LNG IUS compared to hysterectomy as first-line therapy for women with HMB who have no other pelvic pathology. One randomized 10-year study comparing LNG IUD use to hysterectomy found that 54% of women who randomized to the LNG IUD avoided surgery.[19] Reserving hysterectomy for use only in women with pelvic pathology and to those who do not respond to LNG IUD therapy would significantly reduce health care costs and risks associated with treatment of HMB.
  • Several other procedures are approved for treatment of women with symptomatic fibroids, including myomectomy, uterine artery embolization of leiomyoma, cryotherapy, and ultrasonic destruction of leiomyoma, etc.

 

In the Pipeline

Newer medical therapies to treat HMB related to leiomyoma may become available in the United States. Selective progesterone receptor modulation (SPRMs) exerts partial progesterone antagonistic effects while maintaining estradiol levels, thus avoiding hypoestrogenism seen with many other hormonal therapies.[20] Characteristic histologic changes seen in the endometrium called PAEC (progesterone receptor modulator associated endometrial changes) look like hyperplasia, but these changes apparently do not have the potential for malignancy. In particular, low-dose ulipristal acetate (UPA) has been found to be very effective in establishing amenorrhea in patients with fibroid-induced anemia to increase hemoglobin prior to myomectomy. Long-term use is being investigated.[21], [22]

 

 

 

[1] Nelson A, Shulman L.   Menstrual Cycle: Normal Patterns, Menstrual Disorders, and Menstrually-Related Problems. In: Hatcher RA, Nelson AL, Trussell J, Cwiak C, Cason P, Policar MS, Edelman A, Aiken ARA, Marrazzo J, Kowal D, eds. Contraceptive technology. 21st ed. New York, NY: Ayer Company Publishers, Inc., 2018.

[2] Bradley LD, Gueye NA. The medical management of abnormal uterine bleeding in reproductive-aged women. Am J Obstet Gynecol 2016;214:31–44.

[3] Lethaby A, Hussain M, Rishworth JR, Rees MC. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev. 2015;(4):CD002126.pub3.

[4] Kaunitz AM, Bissonnette F, Monteiro I, Lukkari-Lax E, Muysers C, Jensen JT. Levonorgestrel-releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol 2010;116:625–32.

[5] ACOG Committee on Adolescent Health Care; Committee on Gynecologic Practice. Committee Opinion No.580: von Willebrand disease in women. Obstet Gynecol 2013;122:1368–73.

[6] Braga GC, Brito MB, Ferriani RA, et al. Oral anticoagulant therapy does not modify the bleeding pattern associated with the levonorgestrel-releasing intrauterine system in women with thrombophilia and/or a history of thrombosis. Contraception 2014;89:48–53.

[7] Abu Hashim H, Ghayaty E, El Rakhawy M. Levonorgestrel–releasing intrauterine system vs oral progestins for non-atypical endometrial hyperplasia: a systematic review and metaanalysis of randomized trials. Am J Obstet Gynecol 2015;213:469–78.

[8] Maybin JA, Critchley HO. Medical management of heavy menstrual bleeding. Womens Health (Lond) 2016;12:27–34.

[9] Maybin JA, Critchley HO. Medical management of heavy menstrual bleeding. Womens Health (Lond) 2016;12:27–34.

[10] Endrikat J, Shapiro H, Lukkari-Lax E, Kunz M, Schmidt W, Fortier M. A Canadian, multicentre study comparing the efficacy of a levonorgestrel-releasing intrauterine system to an oral contraceptive in women with idiopathic menorrhagia. J Obstet Gynaecol Can 2009;31:340–7.

[11] Dahiya P, Dalal M, Yadav A, Dahiya K, Jain S, Silan V. Efficacy of combined hormonal vaginal ring in comparison to combined hormonal pills in heavy menstrual bleeding. Eur J Obstet Gynecol Reprod Biol 2016;203:147–51.

[12] Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception 2003;68:89–96.

[13] Miller L, Verhoeven CH, Hout J. Extended regimens of the contraceptive vaginal ring: a randomized trial. Obstet Gynecol 2005;106:473–82.

[14] Maybin JA, Critchley HO. Medical management of heavy menstrual bleeding. Womens Health (Lond) 2016;12:27–34.

[15] Lethaby A, Duckitt K, Farquhar C. Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev 2013:CD000400.pub3.

[16] Lukes AS, Moore KA, Muse KN, et al. Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol 2010;116:865–75.

[17] Leebeek FW, Eikenboom JC. Von Willebrand’s disease. N Engl J Med 2016;375:2067–2080.

[18] Kaunitz AM, Meredith S, Inki P, Kubba A, Sanchez-Ramos L. Levonorgestrel-releasing intrauterine system and endometrial ablation in heavy menstrual bleeding: a systematic review and meta-analysis. Obstet Gynecol 2009;113:1104–16.

[19] Heliövaara-Peippo S, Hurskainen R, Teperi J, et al. Quality of life and costs of levonorgestrel-releasing intrauterine system or hysterectomy in the treatment of menorrhagia: a 10-year randomized controlled trial. Am J Obstet Gynecol 2013;209:535.e1–535.e14.

[20] Donnez J, Donnez O, Matule D, et al. Long-term medical management of uterine fibroids with ulipristal acetate. Fertil Steril 2016;105:165–173.e4.

[21] Safrai M, Chill HH, Reuveni Salzman A, Shushan A. Selective progesterone receptor modulators for the treatment of uterine leiomyomas. Obstet Gynecol. 2017;130:315–318.

[22] Archer DF, Stewart EA, Jain RI, et al. Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study. Fertil Steril 2017;108:152–160.e4.